Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that the newly optimized AR antagonist 39 demonstrated effective hair growth and safety in a mouse model of androgenetic alopecia, showing comparable efficacy to pyrilutamide with faster response and favorable pharmacokinetics, due to innovative structural design and dual metabolic inactivation strategy.

RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.

This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.

This study concluded that 16β-methyl-17α-benzoyloxypregnen-4-en-3,20-dione may be a promising treatment for androgen-dependent diseases and epilepsy due to its antioxidant effects and impact on GABAergic and serotonergic metabolism in rats.

A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.

Bicalutamide shows promise for treating female hair loss.

This study found that the optimized AR antagonist candidate 39, in a hair-growth mouse model, achieved similar efficacy to pyrilutamide with faster onset and favorable safety, suggesting a promising approach for developing topical treatments with low systemic toxicity for androgenetic alopecia.

This case report describes a 57-year-old woman's virilizing adrenal tumor effectively treated with the antiandrogen cyproterone acetate, which led to symptom reversal and tumor resolution.

In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.

This case report presents the first successful treatment of acne keloidalis nuchae with a combination of halobetasol 0.01% and tazarotene 0.045% lotion.

Bicalutamide mesotherapy improved hair density in women with hair loss and was well received.

This study found that PNU 157706 is a highly potent inhibitor of human 5α-reductase enzymes, showing a stronger and longer-lasting antiprostatic effect in rats compared to finasteride.

In this study, flutamide at therapeutic doses caused significant histological changes in the testes and epididymis of adult albino rats, reducing androgen receptor immunoreactivity and increasing estrogen receptor immunoreactivity.

This case report highlights an instance of nilotinib-induced keratosis pilaris without alopecia or pruritus, emphasizing the need for awareness to optimize patient outcomes.

This study found that androgen deprivation therapy is associated with an increased risk of acquired long-QT syndrome and Torsades de Pointes, particularly highlighting enzalutamide's greater association with sudden death compared to other therapies.

Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.

This study found that the antiandrogens enzalutamide and bicalutamide reduced SARS-CoV-2 entry and infection in human lung cells by lowering TMPRSS2 levels, suggesting their potential as COVID-19 treatments and supporting clinical trials.

This study found that two novel nonsteroidal derivatives inhibited specific enzymes in vitro and in vivo, leading to dihydrotestosterone accumulation in androgen-dependent glands, suggesting potential therapeutic use for mood improvement in the elderly.

This study found that proxalutamide significantly increased recovery rates, reduced mortality, and shortened hospital stays in hospitalized COVID-19 patients across different regions in Brazil.

This study found that combining flutamide with an oral contraceptive significantly reduced hirsutism, acne, and seborrhea in patients after seven months, without significant side effects.

In this study, dutasteride treatment in retinitis pigmentosa mice increased photoreceptor survival and reduced glial activation, suggesting it may offer a neuroprotective effect.

This study concluded that Flutamide-loaded solid lipid nanoparticles may enhance hair follicle drug delivery and promote hair growth in androgenic alopecia compared to a Flutamide hydroalcoholic solution.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

This study found that while flutamide was very effective in improving hirsutism in women over long-term treatment, a high incidence of adverse effects led to a majority discontinuing the therapy.

This study concluded that a sequential regimen of prednisolone and cyclophosphamide, followed by low-dose prednisolone and azathioprine, achieved favorable results in most patients with diffuse proliferative and/or membranous lupus nephritis without significant toxicities.

In this case study, a neoadjuvant therapy combining gemcitabine and Disitamab Vedotin proved effective and safe for a muscle-invasive bladder cancer patient with severe renal insufficiency, who could not tolerate platinum-based treatments. The study suggests this regimen may be a viable alternative, pending further research.

In this study, researchers found that the NUDT15 R139C gene variant is a significant genetic risk factor for azathioprine-induced severe myelotoxicity in Japanese patients with dermatological conditions, suggesting that screening for this variant may help prevent adverse reactions in East-Asian populations.

This study found that using nanoporous silica entrapped lipid-drug complexes enhanced the solubility and bioavailability of dutasteride in beagle dogs.

In this study, a case of a young Chinese female with a specific NUDT15 genetic variant experienced severe azathioprine-induced myelosuppression and alopecia while treating systemic lupus erythematosus, highlighting the need for routine blood monitoring during treatment to manage AZA intolerance associated with genetic factors.

This case report describes severe agranulocytosis and alopecia in a Japanese woman after starting azathioprine, highlighting the potential role of NUDT15 genetic screening in preventing adverse reactions to the drug.